	Timing matters: radiation necrosis risk of antibody-drug conjugates (ADCs) combined with radiation therapy in breast cancer brain metastases: a systematic review and comparative meta-analysis. Neurosurg Rev Zare A, Zare A, Kiani I, Delbari P, Mortezaei A, Ahmadvand MH, Rashidi F, Mohammadzadeh I, Azarmi E, Ghalehtaki R, Tafakhori A. PMID: 41748827 [PubMed - in process]
	CMAF-Net: cross-modal attention fusion with information-theoretic regularization for imbalanced breast cancer histopathology. Sci Rep Ativi WX, Chen W, Kwao L, Ayivi W, Sam F, Alqahtani A, Gu YH, Al-Antari MA. PMID: 41748602 [PubMed - as supplied by publisher]
	No evidence for genotype-treatment interactions with breast cancer endocrine therapy adverse effects in UK Biobank. NPJ Breast Cancer Mokbel K, Weedon MN, Moye V, Ruth KS, Jackson L. PMID: 41748588 [PubMed - as supplied by publisher]
	Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. Value Health Shu Y, Tang Y, Ding Y, Zhang W, Zhang Q. PMID: 41747823 [PubMed - as supplied by publisher]
	Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial. ESMO Open Paracchini L, Velle A, Di Gennaro P, Mannarino L, Ancona L, Lorusso D, Cecere SC, Colombo N, Beltrame L, Fagotti A, Tasca G, Piemontese M, Arenare L, Califano D, Galdiero F, Zadro R, Chiodini P, Perrone F, Biagioli E, D'Incalci M, Romualdi C, Pignata S, Marchini S. PMID: 41747586 [PubMed - as supplied by publisher]
	Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. Expert Opin Investig Drugs Thaker PH, Lindborg SR, Limon A, Faller DV, Bradley WH, Anwer K, Alvarez RD. PMID: 41746995 [PubMed - as supplied by publisher]
	Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy. Breast Cancer Res Treat Drozd C, Curtit E, Jacquinot Q, Roux P, Paget-Bailly S, Gillet V, Meneveau N, Mougin F. PMID: 41746533 [PubMed - in process]
	Spatial Patterns of Breast Cancer Risk Associated with Industrial and Environmental Pollutants: A Scoping Review. Toxics Nahal D, Hoffpauir A, Kinariwala K, Tetteh P, Orenge F, Patel A, Ghalib A, Northeim K. PMID: 41745813 [PubMed]
	Dynamic Contrast-Enhanced MRI Kinetic Curve-Driven Parametric Radiomics for Predicting Breast Cancer Molecular Subtypes: A Multicenter and Interpretable Study. Tomography Wang T, Gong J, Wang S, Sun S, Zhou J, Lin L, Zhang D, You C, Gu Y. PMID: 41745704 [PubMed - in process]
	Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review. Diseases Tanase-Damian C, Antone NZ, Paun DL, Tanase I, Achima. PMID: 41745089 [PubMed]
	Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer. Curr Oncol Guo S, Addison CL. PMID: 41744893 [PubMed - in process]
	Estrogen Receptor-Low Positive (ER-Low) Breast Cancer: A Unique Clinical and Pathological Entity. Curr Oncol Faa G, Lai E, Ziranu P, Pretta A, Tiwari E, Dessì M, Solinas C, Saba G, Loi F, Codipietro C, Graziano S, Ottelio L, Dessena M, Coghe F, Suri JS, Saba L, Scartozzi M. PMID: 41744886 [PubMed - in process]
	Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC). Curr Oncol Median MD, Antone NZ, Volov, Mazilu L, Negru , Curc, Ni, P, Ungureanu A, Lupu V, Oprean CM. PMID: 41744884 [PubMed - in process]
	Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025. Curr Oncol Sehdev S, Joy AA, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Gelmon KA, Jerzak KJ, Kumar A, Laing K, LeVasseur N, Simmons C, Webster M, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada. PMID: 41744876 [PubMed - in process]
	Understanding Patients' Preferences for Discussing Sexuality After Surgery-A Qualitative Study of Sexuality and Body Image in Women with Ovarian Cancer. Curr Oncol Stöckl JR, Lee MM, Sehouli J, Pirmorady-Sehouli A. PMID: 41744874 [PubMed - in process]
	Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. Curr Oncol Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada. PMID: 41744870 [PubMed - in process]
	Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy. Curr Oncol Li T, Zhang T, Dang Y, Lin Y, Li X, Ling X. PMID: 41744856 [PubMed - in process]
	DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential. Curr Oncol Niture S, Thotala D, Jaboin J, Seneviratne D. PMID: 41744846 [PubMed - in process]
	Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. Curr Oncol Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S. PMID: 41744845 [PubMed - in process]
	High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report. Curr Oncol Eisen A, Bane A, Causer P, Cordeiro E, Fienberg S, Kornecki A, Kulkarni A, Hong NL, Mancuso T, Muradali D, Nofech-Mozes S, Roberts A, Shaheen R, Courtney S, Grove R, Brackstone M. PMID: 41744831 [PubMed - in process]

Articles 1 - 20 / 324955

Page 1 of 16248



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy